Risk factors associated with Helicobacter pylori infection treatment failure in a high prevalence area by Yakoob, Javed et al.
Risk factors associated with Helicobacter pylori infection
treatment failure in a high prevalence area
J. YAKOOB*, W. JAFRI, Z. ABBAS, S. ABID, S. NAZ, R. KHAN AND A. KHALID
Department of Medicine, The Aga Khan University, Karachi, Pakistan
(Accepted 21 April 2010; ﬁrst published online 7 June 2010)
SUMMARY
Triple therapy is commonly used for the treatment of Helicobacter pylori infection. We
determined risk factors associated with its failure in compliant patients focusing on H. pylori
density, virulence marker and 23S ribosomal RNA (rRNA) point mutations associated with
clarithromycin resistance. H. pylori infection was diagnosed by 14C urea breath test (14C UBT)
and rapid urease test or histology. Triple therapy with esomeprazole 20 mg b.i.d., amoxicillin 1 g
b.i.d. and clarithromycin 500 mg b.i.d. was prescribed for 10 days. 14C UBT was repeated 4 weeks
after treatment. In total, 111 patients [69 (62%) males] with a mean age of 46¡16 years were
enrolled. The mean age of treatment failure was 39¡14 years compared to 48¡16 years with
eradication (P=0.002). Treatment failure was associated with younger mean age, point mutations
in the 23S rRNA gene of H. pylori and vacA s1a and m1 when associated with cagA negativity.
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INTRODUCTION
The Gram-negative bacterium, Helicobacter pylori,
colonizes the human stomach, with prevalence
rates from 25% in Western countries to over 90%
in developing countries [1, 2]. H. pylori plays a sig-
niﬁcant role in the pathogenesis of gastritis and peptic
ulcer disease, low-grade mucosa-associated lymphoid
tissue lymphoma, and gastric carcinoma (GC) [3, 4].
Its eradication dramatically aﬀects the natural history
of both peptic ulcer and gastric lymphoma [5].
European and U.S. guidelines advised the use of
triple therapies [proton-pump inhibitor (PPI), clari-
thromycin+amoxicillin, or metronidazole] for 7–14
days to cure this infection [6]. However, H. pylori
resistance against clarithromycin is increasing
worldwide, reducing the success rate of standard triple
therapies to mean values as low as 18–44% in some
part of the world [7, 8]. In a previous multicentre study
in patients with active duodenal ulcer, 1-week triple
therapy with PPI, amoxicillin+clarithromycin eradi-
cated H. pylori infection with per protocol (PP) rates
of 72% and 62%, respectively, with intention to treat
(ITT) analysis in patients recruited from Pakistan [8].
Low cure rate and a higher resistance to clari-
thromycin are observed in H. pylori-positive patients
with functional dyspepsia than for peptic ulcer disease
[9–11]. Clarithromycin resistance, the major cause of
H. pylori treatment failure, is associated with point
mutations within the peptidyltransferase-encoding
region in domain V of the 23S rRNA gene [12]. These
mutations include A2142G or C, A2143G or C,
A2115G, G2141A, and A2142T [12–14]. These com-
mon mutations can be detected using polymerase
chain reaction (PCR)–DNA enzyme immunoassay,
PCR line probe assay, and real-time PCR [15–17]. The
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method of detecting H. pylori by PCR directly on
DNA derived from gastric biopsy specimens, and de-
tection of macrolide resistance with PCR–restriction
fragment length polymorphism (PCR–RFLP) directly
on biopsy specimens, have been evaluated previously
[18–20]. Peptic ulcer disease is commonly associated
with cytotoxin-associated gene (cagA)-positive and
vacuolating cytotoxin gene (vacA) s1-type strains
[21, 22]. Therefore, the cagA and vacA subtypes and
bacterium-related histopathological lesions may play
an important role in H. pylori eradication. The aim of
this study was to determine the factors associated with
treatment failure and prevalence of point mutations
directly from gastric biopsy and to investigate the
eﬀect of these mutations and H. pylori genotypes
on eradication therapy using PPI, clarithromycin+
amoxicillin for 10 days.
MATERIALS AND METHODS
Patients
A total of 111 patients undergoing diagnostic oeso-
phagogastroduodenoscopy (OGD) for various symp-
toms in the endoscopy suite of the Department of
Gastroenterology were enrolled from January 2007
to December 2008. There were 69 male patients
(male: female ratio 1.65:1). The mean age of patients
was 46¡16 years (range18–82 years). Informed con-
sent was obtained for the study and for OGD with
biopsies from antrum and corpus of the stomach. The
study was approved by the institutional ethics review
committee of The Aga Khan University, Karachi. At
the time of enrolment, clinical symptoms, physical
ﬁndings and previous drug treatment, dosage and
duration were noted. The patients enrolled had not
received previous treatment with antibiotics, PPIs,
histamine 2-receptor blockers (H2-RB) and bismuth
compounds. Seventy-six (69%) patients were diag-
nosed as non-ulcer dyspepsia with gastritis, nine (8%)
as gastric ulcer, 16 (14%) as GC, and 10 (9%) as
duodenal ulcer. Sydney classiﬁcation of endoscopic
gastritis according to localization was used to classify
it as pangastritis, gastritis of the body and antral
gastritis [21]. Gastric biopsy specimens were obtained
from an erythematosus area of the antrum and cor-
pus. In the case of a lesion, ulcer or suspected malig-
nancy, biopsy was taken from both the involved and
uninvolved mucosa. Biopsy specimens, two each were
obtained for rapid urease test, histology and DNA
extraction for PCR. Patients with H. pylori infection
were diagnosed on the basis of rapid urease test and
histology. They were treated with triple therapy
comprising of PPI, esomeprazole 40 mg b.i.d., clari-
thromycin 500 mg b.i.d. and amoxicillin 1 g b.i.d. for
10 days. Eradication of H. pylori infection was docu-
mented by 14C urea breath test (UBT) performed
4 weeks after completion of treatment. Patients were
advised not to take PPIs and to use an antacid if
symptomatic before the UBT. At the end of treat-
ment, 44 (40%) patients were positive, and 53 (47%)
were negative by 14C UBT, and for 14 (13%) with GC
the test could not be done.
Rapid urease test
Pronto Dry (Medical Instrument Corp., Switzerland)
results were read in 30 min after sampling according
to the manufacturer’s instructions. The colour change
from yellow to pink was considered positive [22].
Histology
Gastric biopsy specimens for histopathology were
stained with haematoxylin and eosin (H&E) stain
for the detection of H. pylori and degree of gastritis.
In doubtful cases Giemsa staining was performed to
ascertain the presence of H. pylori. The degree of
gastritis as determined on H&E stain was scored in
accordance with the Sydney system [23]. Histological
features of gastritis were graded according to the up-
dated Sydney System by an experienced pathologist.
Mononuclear cell inﬁltration, glandular atrophy, and
intestinal metaplasia were recorded on a four-point
scale (0, normal ; 1, mild; 2, moderate ; 3, marked).
Polymorphonuclear cell inﬁltration was coded as
present (1) or absent (0) at biopsy sites. Acute or
chronic inﬂammation was deﬁned as presence of
features of both acute and chronic inﬂammation. The
criteria for diagnosis of GC were the presence of acini
lined by atypical cells, abnormal mitoses, sheets of
signet ring cells with intracellular mucin. Special
stain for acid mucin (PAS Alcine Blue) was performed
in diﬃcult cases. In undiﬀerentiated cases, immuno-
histochemical epithelial markers, i.e. cytokeratins
highlighted the tumour cells [24].
Gastric biopsy specimens for histopathology were
stained with H&E stain for the detection of H. pylori
and degree of gastritis. In doubtful cases, Giemsa
staining was performed to ascertain the presence of
H. pylori. The degree of gastritis as determined on
H&E stain was scored in accordance with the Sydney
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system [17]. The presence of H. pylori was determined
by the positive rapid urease test and histology. All
biopsy specimens for histological examination were
ﬁxed in 10% formalin, embedded in paraﬃn wax on
the oriented edge, and cut into 5-mm-thick sequential
sections. All tissue sections were stained with H&E for
histological examination. The degree of acute and
chronic inﬂammation, as well as the H. pylori density
was scored according to the updated Sydney system.
Bacterial density was graded from 0 to 3 (0, absent ;
1–3, from few and isolated bacteria to colonies). The
inﬁltration of gastric mucosa by mononuclear cells
and polymorphonuclear leucocytes, atrophy, and in-
testinal metaplasia were graded on a four-point scale
(0, none; 1, mild; 2, moderate; 3, marked). Chronic
inﬂammation was deﬁned according to an increase in
lymphocytes and plasma cells in the lamina propria
graded into mild, moderate or marked increase in
density. Chronic active gastritis indicated chronic in-
ﬂammation with neutrophilic polymorph inﬁltration
of the lamina propria, pits or surface epithelium
graded as: 0=nil ; mild, <33% of pits and surface
inﬁltrated; moderate, 33–66%; and marked >66%.
Antrum and corpus gastritis were scored by total sum
of grade of gastritis (1, mild; 2, moderate; 3, marked,
inﬁltration with lymphocytes and plasma cells) and
activity of gastritis (1, mild; 2, moderate ; 3, marked,
inﬁltration with neutrophilic granulocytes) either in
the antrum or in the corpus, a maximum sum of 6
points for each individual patient. Atrophy was de-
ﬁned as the loss of inherent glandular tissue, with or
without replacement by intestinal-type epithelium.
For optimal histological evaluation, all gastric biopsy
specimens included surface epithelium and muscularis
mucosae. Lymphoid aggregates were deﬁned as ac-
cumulations of lymphocytes and plasma cells without
a germinal centre.
Tissue DNA extraction
DNA was extracted from gastric tissue as previously
described [25]. Brieﬂy, gastric tissue was homogenized
to uniformity in 500 ml sterile water and centrifuged at
12 000 g for 3 min. Next 500 ml lysis buﬀer [100 mM
NaCl, 10 mM Tris–HCl (pH 8.0), 25 mM EDTA, 0.5%
sodium dodecyl sulfate], and 10 ml Proteinase K
(10 mg/ml) were added. Incubation was performed
at 50 xC for 20 h; this was followed by phenol–
chloroform extraction and ethanol precipitation. The
resulting pellet was allowed to dissolve in 40 ml TE
buﬀer [10 mM Tris–HCl (pH 7.4) and 0.1 mM EDTA
(pH 8.0)] for 20 h at 37 xC. Samples were stored at
x20 xC before PCR ampliﬁcation was performed.
DNA content and purity was determined by measur-
ing the absorbance at 260 nm and 280 nm using a
spectrophotometer (Beckman DU-600, USA).
PCR
Ampliﬁcation of cag A and vac A alleles by PCR was
performed in a volume of 50 ml containing 10 mmol/l
Tris–HCl (pH 8.3), 50 mmol KCl, 1.5–2.5 mmol/l
MgCl2, 200 mmol/l deoxynucleoside triphosphates,
2 U Taq DNA polymerase (Promega, USA) and
25 pmol of both forward and reverse primers (syn-
thesized by anMWGAutomatic synthesizer) (Table 1)
used previously [26]. PCR was performed in a
PerkinElmer 9700 thermal cycler. Positive and nega-
tive reagent control reactions were performed with
each batch of ampliﬁcations. DNA from H. pylori
strains ATCC 43504 (vacA s1am1, cagA positive),
ATCC 51932 (vacA s2m2, cagA negative) and ATCC
43526 (vacA s1bm1, cagA positive) were used to deﬁne
the accuracy of the cagA. The ampliﬁed PCR pro-
ducts were resolved in 2% agarose gels containing
Tris/acetate/EDTA, stained with ethidium bromide,
and visualized under a short wavelength ultraviolet
light source.
A 267-bp fragment of the 23S rRNA gene of
H. pylori (GenBank accession no. U27270) was
ampliﬁed by PCR using extracted DNA using primers
as previously described corresponding to nucleotides
1931 to 1952 and 2197 to 2175 (Table 1) [27, 28]. PCR
ampliﬁcation was performed in a total volume of
50 ml containing 1rPCR reaction buﬀer, 1.5 mM
MgCl2, 200 mM each of the four dNTPs, 0.2 mM of
primers (synthesized by MWG), 2 U Taq DNA poly-
merase (Promega) and 2 ml of extracted DNA.
Negative reagent control reactions were performed
with each batch of ampliﬁcations, consisting of tubes
containing DNA isolated from biopsies of H. pylori-
negative patients. After ampliﬁcation PCR products
were ethanol precipitated, the pellets were washed
with 70% ethanol and resuspended in 25 ml sterile
distilled water. Then, 3 ml PCR product was electro-
phoresed on a 2% agarose gel to ensure homogeneity
and yield. PCR ampliﬁcation resulted in a homo-
geneous DNA fragment of the expected size.
PCR–RFLP
The ampliﬁed products obtained by PCR were sub-
jected to restriction endonuclease digestion for 2 h at
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37 xC in 20 ml volume, according to recommended
procedures [29]. The digested samples were analysed
by agarose gel (3%, w/v) electrophoresis. Restriction
enzyme BbsI (5 U), BsaI (5 U) and BceAI (0.5 U)
(New England Biolabs, USA) were used on the basis
of sequence data available for this ampliﬁed product.
RFLP allowed the identiﬁcation of mutations
A2142G and A2143G using the BbsI and BsaI
restriction enzymes, respectively, as previously de-
scribed [17, 18]. The enzyme BceAI recognized
two sites on the 267-bp ampliﬁed product : 5k-
ACGGC(N)122N-3k and 5k-N2(N)12GCCGT-3k
yielding two restriction fragments from the wild type
and three fromA2142G and A2143Gmutants 195, 48,
24, while BceAI yielded four from A2142C mutation
recognizing an additional site, 5k-ACGGC(N)122N-3k
(Fig. 1). The ampliﬁed PCR products were resolved in
3% agarose gels containing Tris/acetate/EDTA,
stained with ethidium bromide, and visualized under a
short wavelength ultraviolet light source.
Statistical assessment
SPSS software was used for data analysis (version
11.5, SPSS Inc., USA). The descriptive analysis was
done for demographic and clinical features. Results
are presented as mean¡standard deviation for
quantitative variables and number (percentage) for
qualitative variables. Diﬀerences in proportion were
assessed using Pearson’s x2, Fisher’s exact or likeli-
hood ratio tests where appropriate. P value <0.05
was considered as statistically signiﬁcant, all P values
were two-sided.
RESULTS
All patients completed the therapy. After triple
therapy, repeat 14C UBT was negative in 51 (46%)
patients, positive in 44 (40%) while 16 (14%) did not
50 bp
250 bp
150 bp
M A B C D E
Fig. 1.Representative polymerase chain reaction–restriction
fragment length polymorphism (PCR–RFLP) pattern of
23S rRNA genes from patients with clarithromycin resist-
ance. Lane M, DNA size marker ; PCR–RFLP pattern ob-
tained with BbsI (lane A); BsaI (lane B) ; BceAI (lane C).
Table 1. Oligonucleotide primers used in typing of H. pylori cagA and vacA alleles
Region
ampliﬁed
Primer
designation Primer sequence (5k to 3k)
Size of PCR
product PCR cycles
cagA
C-5k D008 GGTCAAAATGCGGTCATGG 297 bp19 1 cycle of 94 xC for 5 min,
35 cycles of 94 xC for 1 min,
55 xC for 1 min and 72 xC
for 90 s, 1 cycle of 72 xC
for 5 min
R008 TTAGAATAATCAACAAACA-
TCACGCCAT
vac A alleles
S1a SS1-F GTCAGCATCACACCGCAAC 190 bp19 1 cycle of 95 xC for 5 min;
35 cycles of 95 xC for 1 min,
52 xC for 1 min and 72 xC
for 1 min; 1 cycle of 72 xC
for 5 min
VA1-R CTGCTTGAATGCGCCAAAC
S1b SS3-F AGCGCCATACCGCAAGAG 187 bp19
VA1-R CTGCTTGAATGCGCCAAAC
S2 SS2-F GCTAACACGCCAAATGATCC 199 bp19
VA1-R CTGCTTGAATGCGCCAAAC
m1 VA3-F GGTCAAAATGCGGTCATGG 290 bp19
CCATTGGTACCTGTAGAAAC
m2 VA3-R
VA4-F GGAGCCCCAGGAAACATTG 352 bp19
VA4-R CATAACTAGCGCCTTGCAC
23S rRNA HPY-S AGGTTAAGAGGATGCGTCAGTC 279 bp29 1 cycle of 94 xC for 5 min,
35 cycles of 94 xC for 1 min,
55 xC for 1 min and 72 xC
for 1 min and 1 cycle of
72 xC for 5 min
HPY-A CGCATGATATTCCCATTAGCAGT
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receive a repeat 14C UBT to document eradication of
infection. Those with a negative 14C UBT had a mean
age of 48¡16 years. There were 44 (40%) patients
with treatment failures with a positive 14C UBT [29
(54%) males, 15 (37%) females], with a mean age of
39¡14 years (range 23–53 years). The most frequent
side-eﬀects were nausea experienced by 30 (34%) and
diarrhoea by 18 (20%) patients. Failure to eradicate
H. pylori infection was seen in 40 (53%) of gastritis
patients (P=0.02) (Table 2a).
Distribution of histopathological changes
The density of H. pylori was of grade 1 in 37 (39%)
and grade 2 in 58 (61%) patients. H. pylori density of
grades 1 and 2 were seen with moderate inﬂammation
in 37 (42%) and 56 (58%) patients compared to nine
(37%) and 15 (63%) with mild inﬂammation, re-
spectively (P=0.658). In treatment failure, moderate
inﬂammation was present in 38 (49%) compared to
mild inﬂammation in six (35%) patients (P=0.315)
(Table 2). The features of lymphoid aggregates,
intestinal metaplasia and gastric atrophy were not
signiﬁcantly associated with H. pylori eradication
(Table 2). One (1%) patient with gastric atrophy and
three (3%) with intestinal metaplasia were diagnosed
as GC. No histopathological changes were associated
with H. pylori treatment failures (Table 2a).
Distribution of virulence markers
The H. pylori virulence marker cagA was positive in
55 (49%), vacA s1a in 68 (61%), vacA s1b in 38
(34%), vacA m1 in 59 (53%) and vacA m2 in 63
(57%) of patients. CagA-positive strains (n=19,
45%) were not more readily eradicated compared to
cagA-negative strains (n=23, 55%) (P=0.85)
(Table 2a). VacA s1a was positive in 31 (56%,
P=0.02), vacA s1b in eight (30%, P=0.04), vacA m1
in 28 (58%, P=0.02) and vacA m2 in 19 (33%, P=
0.002) patients, respectively, with treatment failure
(Table 2a). When cagA was negative VacA s1a
(n=18, 75%, P<0.001), m1 (n=16, 89%, P<0.001)
and s1am1 (n=15, 79%, P=0.001) were associated
with treatment failure (Table 2b).
Distribution of mutations
Overall 55 mutations were present in 44 (40%)
patients. The commonest mutation was 2142G present
in 26 (27%) patients while 12 (12%) had multiple
mutations (Fig. 1) (Table 2a). The mutations con-
comitantly present were 2142G and 2143G seen in
nine (9%) and 2142G, 2143G and 2142C seen in three
(3%) patients (Table 2). The distribution of muta-
tions were not associated with age and gender (P=
0.07 and P=0.795, respectively).
Diagnosis and histological changes associated
with mutations
These mutations were seen in 36 (47%, P=0.009)
gastritis cases with a very low rate of mutations in
patients with GC (n=1, 6%). These mutations were
associated with moderate degree of inﬂammation in
37 (43%, P=0.236) and inﬂammatory activity in 19
(38%, P=0.749) patients. The predominant mutation
A2142G was also associated with endoscopic gastritis
in 21 (28%, P=0.021) and moderate inﬂammation in
13 (26%, P=0.562) patients (Table 2a).
Failure of triple therapy associated with mutations
Triple therapy failure was associated with mutations
in 34 (79%, P<0.001) patients (Table 2). Mutation
A2142G was associated eradication failure in 21
(81%, P<0.001), A2143G in 17 (89%, P<0.001)
and A2142C in seven (78%, P=0.04) patients
(Table 2a).
DISCUSSION
In this study, triple therapy failed to eradicate H.
pylori infection in a large number of patients who
presented at a younger age with gastritis compared
to those with successful eradication (Table 2a). Triple
therapy failure was signiﬁcantly observed in 53%
with gastritis compared to gastric ulcer and duodenal
ulcer (Table 2a). There was also a high frequency of
point mutations 47% in patients with gastritis. How-
ever, mutations were signiﬁcantly negative in our
patients with GC compared to those with gastritis.
Mutations were not associated with grade or activity
of inﬂammation. The mutations observed in gastritis
may have occurred subsequent to previous treatments
with antibiotics. It is known that there is a high fre-
quency of mutation in the strains caused by variation
in the eﬃciency of DNA repair functions or alterna-
tively, in the accuracy of DNA polymerase [30]. In the
presence of an antibiotic all bacteria in the stomach
die and there is a stepwise selection from sensitive to
resistant to compensated mutant [30].
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Table 2a. Factors associated with eradication failure
Total no. of patients (N=111)
Eradication
P value
Failure,
n (%)
Successful,
n (%)
Patients with repeat UBT 95 44 (46) 51 (54)
Age (years) 39¡14 48¡16 0.002
Gender
Male 54 (57) 29 (54) 25 (46) 0.09
Female 41 (43) 15 (37) 26 (63)
Diagnosis
Gastritis 76 (80) 40 (53) 36 (47) 0.02
Gastric ulcer 9 (9) 1 (11) 8 (89)
Duodenal ulcer 10 (11) 3 (30) 7 (70)
Histopathology
H. pylori colonization density
Grade 0
Grade 1 37 (39) 15 (41) 22 (59) 0.367
Grade 2 58 (61) 29 (50) 29 (50)
Grade 3
Inﬂammation
Grade 0
Grade 1 17 (18) 6 (35) 11 (65) 0.315
Grade 2 78 (82) 38 (49) 40 (51)
Grade 3
Activity
Grade 0
Grade 1 52 (55) 24 (46) 28 (54) 0.972
Grade 2 43 (45) 20 (47) 23 (53)
Grade 3
Lymphoid aggregate
Positive 44 (46) 21 (48) 23 (52) 0.795
Negative 51 (54) 23 (45) 28 (55)
Virulence marker
cagA
Positive 42 (44) 19 (45) 23 (55) 0.85
Negative 53 (56) 25 (47) 28 (53)
vacA s1a
Positive 55 (58) 31 (56) 24 (44) 0.02
Negative 40 (42) 13 (32) 27 (68)
s1b
Positive 27 (28) 8 (30) 19 (70) 0.04
Negative 68 (72) 36 (53) 32 (47)
m1
Positive 48 (51) 28 (58) 20 (42) 0.02
Negative 47 (49) 16 (24) 31 (76)
m2
Positive 57 (60) 19 (33) 38 (67) 0.002
Negative 38 (40) 25 (66) 13 (34)
Point mutation
Over all
Positive 43 (45) 34 (79) 9 (21) <0.001
Negative 52 (55) 10 (19) 42 (81)
Individual
A2142G
Positive 26 (27) 21 (81) 5 (19) <0.001
Negative 69 (73) 23 (33) 46 (67)
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The great majority of vacA s1 strains are known to
be associated with a good response to treatment when
associated with cagA [12]. However, the majority of
our patients that were vacA s1a had an eradication
failure since 47% of them were cagA negative.
Previously, it has been shown that cagA-negative
strains s2/m2 were resistant to therapy compared to
the cagA-positive s1am1 or s1am2 strains [12]. The
virulence genotype is an important determinant for
the severity of the gastritis and the formation of
intestinal metaplasia.
The implications of our study are that H. pylori
infection with point mutations signiﬁes a greater
probability of treatment failure. These mutations
were seen with H. pylori infections that were cagA
positive in only 33% of cases. It is known that the
cagA protein produced by certain H. pylori strains
plays a crucial role in gastric carcinogenesis [31].
Moreover, vacA s1 and vacA m1 strains that are
known to be associated with a higher degree of in-
ﬂammation and epithelial damage in the gastric mu-
cosa were positive in only 24–42% ofH. pylori strains
with mutations [32, 33]. Patients with GC are known
to have much more severe gastritis that leads to a de-
crease in acid production and subsequent develop-
ment of GC. This reduction in acid production results
in the suppression of a defence mechanism against de-
diﬀerentiated epithelium that leads to persistence, and
progression to atypical cells [34, 35]. In our study the
mutations were associated with only mild to moderate
inﬂammation and inﬂammatory activity (P=0.236
and 0.749, respectively). However, these were not
signiﬁcant associations.
The presence of either mutation, especially the
A2142G and 2143G may prompt a high-dose, non-
macrolide-based treatment regimen. Recent data
from Western Europe indicate that >60% of treat-
ment failures with clarithromycin-based protocols
are associated with the presence of clarithromycin-
resistant H. pylori isolates after therapy [36]. Our re-
sults are similar to a study from Korea that revealed
the A2142G mutation was observed in 59% of cases
[37], and diﬀerent from those of Japan and China
where the major type of mutation was reported as
A2143G [38, 39]. In studies from USA, the prevalence
of clarithromycin-resistant H. pylori mutant strains
with the A2142G mutation varies from 48% to 53%,
A2143G from 39% to 45% and A2142C from 0%
to 7% [16, 37, 38]. In Europe, the prevalence of
the A2142G mutation was reported as 23–33%, the
A2143G mutation as 44–67%, and the A2142C mu-
tation as 2–10% [18]. In Japan,>90% of the mutant
strains had the A2143G mutation [38]. In a Chinese
study, the A2143G mutation was present in 100% of
clarithromycin-resistant H. pylori strains [39]. Clari-
thromycin resistance was present in 17% of Iranian
H. pylori strains, with 74% having the A2143G mu-
tation, 21% A2142C and 5% A2142G mutations
[40]. These mutations have a genetic stability and
growth advantage compared to the wild-type strain
[41]. Moreover, the A2143G mutation is known to
give a high level of resistance to clarithromycin [41].
Table 2a (cont.)
Total no. of patients (N=111)
Eradication
P value
Failure,
n (%)
Successful,
n (%)
A2143G
Positive 19 (20) 17 (89) 2 (11) <0.001
Negative 76 (80) 27 (43) 49 (57)
A2142C
Positive 9 (9) 7 (78) 2 (22) 0.04
Negative 86 (91) 37 (43) 49 (57)
More than one
2142G+2143G
Positive 9 (9) 9 (100) 0 <0.001
Negative 86 (91) 35 (41) 51 (59)
2142C+2142G+2143G
Positive 3 (3) 3 (100) 0 0.03
Negative 92 (97) 41 (45) 51 (55)
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This suggests that GC is associated with wildH. pylori
strains without 23rRNA mutations in our patients.
The prevalence of GC in our population is lower than
in Japan and China where the prevalence of GC
is higher and clarithromycin-resistant mutations are
less prevalent, i.e. 9% and 5%, respectively [38, 39].
Moreover, a high frequency of clarithromycin-
resistant mutation is described in H. pylori isolates
from Tehran, Iran which is an area without a high
incidence of GC [39]. This suggests that GC in the
Japanese and Chinese populations is related to wild-
typeH. pylori strains without clarithromycin-resistant
mutations. H. pylori strains become resistant by
mutations in the chromosomal genes, by acquisition
of exogenous DNA by plasmids, transposons or
integrons, or by transformation. In conclusion, 23S
rRNA point mutations were prevalent in H. pylori
infection associated with non-ulcer dyspepsia. The
eradication failure of H. pylori infection was associ-
ated with younger mean age, point mutations in
the 23S rRNA gene of H. pylori and vacA s1a and m1
when cagA was negative.
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Table 2b. Association of cagA and vacA with treatment
vacA
cagA
Positive (n=42) Negative (n=53)
Treatment
failure
n (%)*
Treatment
successful
n (%) P value
Treatment
failure
n (%)
Treatment
successful
n (%) P value
s1a
Positive 13 (42) 18 (52) 0.504 18 (75) 6 (25) <0.001
Negative 6 (55) 5 (45) 7 (24) 22 (76)
s1b
Positive 3 (37) 5 (63) 0.709 5 (26) 14 (74) 0.043
Negative 16 (47) 18 (53) 20 (59) 14 (41)
m1
Positive 12 (40) 18 (60) 0.323 16 (89) 2 (11) <0.001
Negative 7 (58) 5 (42) 9 (26) 26 (74)
m2
Positive 7 (37) 12 (63) 0.366 12 (32) 26 (68) 0.001
Negative 12 (52) 11 (48) 13 (87) 2 (13)
s1am1
Positive 11 (44) 14 (56) 0.845 15 (79) 4 (21) 0.001
Negative 8 (47) 9 (53) 10 (29) 24 (71)
s1bm1
Positive 2 (33) 4 (67) 0.673 2 (67) 1 (33) 0.597
Negative 17 (47) 19 (53) 25 (46) 27 (54)
s1am2
Positive 4 (33) 8 (67) 0.495 5 (56) 4 (44) 0.719
Negative 15 (50) 15 (50) 20 (45) 24 (55)
s1bm2
Positive 1 (20) 4 (80) 0.356 4 (25) 12 (75) 0.041
Negative 18 (49) 19 (51) 21 (57) 16 (43)
Diﬀerences in proportion were assessed by using Pearson’s x2, Fisher’s exact or likelihood ratio tests where appropriate.
P value<0.05 was considered as statistically signiﬁcant, all P values were two-sided.
* n (%)=number and percentage.
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